Treatment

Treatment should be individualized. The goal is not only to reduce bacterial overgrowth, but also to identify and address the reason it developed.

Treatment Goals

A reasonable treatment plan asks:

1. Is SIBO the likely cause of symptoms?
2. Is testing needed before treatment?
3. Are there red flags or alternative diagnoses?
4. What underlying factor is driving recurrence risk?
5. Are there nutritional deficiencies to correct?

Antibiotics

Antibiotics are commonly used for confirmed or strongly suspected SIBO. The specific antibiotic depends on the clinical scenario, gas pattern, prior treatment, allergies, local practice, and clinician judgment.

Patients should not repeat antibiotics indefinitely without reassessment.

Patients who cannot tolerate or access rifaximin may discuss alternatives with their clinician. See Herbal Antimicrobials for SIBO for a summary of botanical antimicrobial evidence, including the Chedid et al. comparison with rifaximin.

Treating the Underlying Cause

SIBO often recurs if the underlying cause persists. Management may include attention to:

• motility disorders
• constipation
• prior surgical anatomy
• pancreatic insufficiency
• inflammatory bowel disease
• celiac disease
• diabetes control
• medication effects

Nutrition

Some patients need testing or supplementation for deficiencies, especially if they have weight loss, anemia, diarrhea, or malabsorption.

Potential deficiencies include:

• vitamin B12
• iron
• vitamin D
• fat-soluble vitamins
• protein-calorie malnutrition in severe cases

Diet

Diet may reduce symptoms but should not be treated as a universal cure. Restrictive diets should be used carefully, especially in patients with weight loss, eating disorder history, nutritional deficiency, or medically complex disease.

If Symptoms Do Not Improve

Failure to improve after treatment should prompt reassessment. Possibilities include:

• incorrect diagnosis
• incomplete response
• recurrence
• constipation or motility disorder
• another gastrointestinal condition
• medication adverse effect
• dietary trigger unrelated to SIBO

Persistent IBS-Type Symptoms After SIBO Treatment

Some patients continue to have IBS-type symptoms even after SIBO has been treated or breath testing has normalized. In this situation, the problem may no longer be active bacterial overgrowth alone. SIBO-related immune activation and neural sensitization may outlast the bacterial overgrowth itself, leaving behind a sensitized gut-brain axis that continues to generate pain, bloating, urgency, or meal-related symptoms.^[1][2]

This is often described as visceral hypersensitivity: the gut’s sensory nerves and central pain-processing pathways remain more reactive to normal gas, meals, stool movement, or stretching. Treating this component usually requires IBS and gut-brain-targeted therapies rather than repeated antibiotic courses.

Tricyclic antidepressants

Tricyclic antidepressants (TCAs) have the strongest evidence among gut-brain neuromodulators for IBS, especially when abdominal pain is prominent. A 2025 systematic review and meta-analysis of 28 randomized trials including 2,475 patients found that TCAs significantly improved global IBS symptoms (RR 0.70, 95% CI 0.62-0.80) and abdominal pain (RR 0.69, 95% CI 0.54-0.87), with moderate-certainty evidence. This was the highest certainty of any neuromodulator class studied.^[3]

The ATLANTIS trial, a large primary-care trial of 463 adults with IBS, found that low-dose amitriptyline was superior to placebo as a second-line treatment. Participants used 10 mg at bedtime with patient-led titration up to 30 mg based on response and tolerability. At 6 months, IBS Symptom Severity Score improved by 27 points more with amitriptyline than placebo (p = 0.008).^[4]

Practical points to discuss with a clinician:

• Start low: Amitriptyline is often started at 10 mg at bedtime, with gradual titration up to 30 mg based on symptoms and tolerability.^[4][5]
• Choose based on bowel habit: Amitriptyline has stronger anticholinergic effects that slow transit, which may help IBS-D but worsen IBS-C. Nortriptyline or desipramine may be better tolerated when constipation or anticholinergic side effects are a concern.^[5][6][7]
• Expect delayed benefit: Clinical response may take 6-8 weeks. After response, many patients continue treatment for 6-12 months before considering a slow taper.^[5][8]
• Mechanism: At low doses, TCAs appear to reduce visceral afferent signaling, alter central pain processing, improve sleep, and slow GI transit. These effects are distinct from their antidepressant effect at higher doses.^[5][9][10]
• Side effects: Dry mouth, drowsiness, and constipation are common. In ATLANTIS, 13% discontinued amitriptyline due to adverse events vs. 9% with placebo.^[4]

These doses are generally lower than doses used for depression. The goal is pain modulation, improved sleep, and reduced visceral afferent signaling, not treatment of depression alone.

SNRIs and SSRIs

Serotonin-norepinephrine reuptake inhibitors (SNRIs), such as duloxetine or venlafaxine, are usually considered second-line options for pain-predominant symptoms when TCAs are not tolerated or are contraindicated. The 2025 meta-analysis found that SNRIs improved abdominal pain (RR 0.22, 95% CI 0.08-0.59), but this was based on only 2 small RCTs with 94 patients and very-low-certainty evidence.^[3]

• Duloxetine is often favored when IBS symptoms coexist with fibromyalgia, migraine, neuropathic pain, or another chronic pain syndrome. It has stronger evidence in non-GI chronic pain than in IBS-specific trials.^[3][10]
• Venlafaxine has less IBS-specific support than duloxetine and is not usually the first SNRI considered for IBS pain.^[10][11]
• Advantage over TCAs: SNRIs lack anticholinergic effects, so they are less likely to worsen constipation.^[11]
• Evidence gap: Definitive IBS trials are still limited, so SNRIs are usually individualized rather than routine first-line IBS pain therapy.^[6][7]

Selective serotonin reuptake inhibitors (SSRIs) have a more limited role for abdominal pain itself. The 2025 meta-analysis found a modest abdominal pain signal (RR 0.74, 95% CI 0.56-0.99) in 7 RCTs, but with low-certainty evidence.^[3] SSRIs may be useful when anxiety, hypervigilance, panic, depression, or constipation-predominant symptoms are major contributors, but they are not usually the first choice for pain-predominant IBS because they lack the noradrenergic component used for visceral analgesia.^[5][10]

Gut-directed psychotherapy

Gut-directed hypnotherapy (GDH) and cognitive behavioral therapy (CBT) are among the best-studied behavioral treatments for IBS. The ACG guideline supports gut-directed psychotherapies for global IBS symptoms, and a 2020 network meta-analysis of 41 RCTs including 4,072 patients found benefit for self-administered or minimal-contact CBT, face-to-face CBT, and gut-directed hypnotherapy. GDH significantly reduced IBS symptoms (RR 0.67, 95% CI 0.49-0.91).^[12][13]

GDH works through several mechanisms relevant to post-SIBO visceral hypersensitivity:

• down-regulation of visceral afferent signaling through guided imagery and posthypnotic suggestions targeting gut sensations^[10][14]
• modification of central pain processing and symptom-related fear^[15][16]
• reduction of gut-specific anxiety and hypervigilance^[10][12]
• possible effects on smooth muscle activity and gastrointestinal motility^[11][14]

Access is a real barrier because trained clinicians are not available everywhere. A 2025 randomized trial of digitally delivered GDH found that 81% of GDH users achieved a clinically meaningful IBS-SSS improvement of at least 50 points vs. 63% with active control (p = 0.002), and 71% achieved at least 30% pain reduction vs. 35% with active control (p < 0.001).^[17] Digital delivery may help some patients access GDH when a trained therapist is unavailable.^[17][18]

Other options and cautions

Other neuromodulators are sometimes used in selected patients, but the evidence is less mature:

Opioids should generally be avoided for chronic functional GI pain. They can worsen constipation, slow motility, increase SIBO risk, and contribute to opioid-induced hyperalgesia or narcotic bowel syndrome.^[10][19][20]

A practical post-SIBO framework

When IBS-type symptoms persist after SIBO treatment, a clinician may consider:

1. Confirm or reassess SIBO eradication when clinically appropriate. If repeat testing or the clinical story suggests persistent overgrowth, that should be addressed before assuming symptoms are purely hypersensitivity-driven.
2. Look for other drivers. Constipation, bile acid diarrhea, pelvic floor dysfunction, celiac disease, inflammatory bowel disease, pancreatic insufficiency, medication effects, dietary triggers, and recurrent SIBO can all mimic persistent IBS symptoms.
3. Identify the dominant symptom driver:
   • Pain-predominant symptoms: TCA first-line, often amitriptyline for IBS-D and nortriptyline or desipramine when constipation is a concern.
   • Pain with fibromyalgia or widespread chronic pain: Consider duloxetine.
   • Anxiety or hypervigilance-predominant symptoms: Consider CBT, gut-directed hypnotherapy, and sometimes an SSRI.
   • Refractory symptoms: Consider combining medication with GDH or CBT rather than simply repeating antibiotics.
4. Maintain therapy long enough to work. Neuromodulators often need weeks for full benefit, and many patients remain on therapy for 6-12 months after response before tapering slowly.^[5][8]
5. Avoid opioids. Major guidance recommends avoiding centrally acting opioids for disorders of gut-brain interaction because of hyperalgesia, dependence risk, constipation, and narcotic bowel syndrome.^[10][19][20]

The key clinical message is that SIBO eradication may remove a microbial trigger, but neuromodulators and gut-directed psychotherapies address the neural sensitization that can persist independently. Many patients with recurrent or refractory “SIBO symptoms” may actually have residual visceral hypersensitivity that requires gut-brain-targeted therapy rather than repeated antibiotic courses.^[1][5]

References

1. Small Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome. Lin HC. JAMA. 2004;292(7):852-858. <doi:10.1001/jama.292.7.852>
2. Peripheral Mechanisms in Irritable Bowel Syndrome. Camilleri M. The New England Journal of Medicine. 2012;367(17):1626-1635. <doi:10.1056/NEJMra1207068>
3. Efficacy of Gut-Brain Neuromodulators in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Khasawneh M, Mokhtare M, Moayyedi P, Black CJ, Ford AC. The Lancet. Gastroenterology & Hepatology. 2025;10(6):537-549. <doi:10.1016/S2468-1253(25)00051-2>
4. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care (ATLANTIS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Ford AC, Wright-Hughes A, Alderson SL, et al. Lancet (London, England). 2023;402(10414):1773-1785. <doi:10.1016/S0140-6736(23)01523-4>
5. Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When. Hanna-Jairala I, Drossman DA. The American Journal of Gastroenterology. 2024;119(7):1272-1284. <doi:10.14309/ajg.0000000000002800>
6. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. Chang L, Sultan S, Lembo A, et al. Gastroenterology. 2022;163(1):118-136. <doi:10.1053/j.gastro.2022.04.016>
7. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Lembo A, Sultan S, Chang L, et al. Gastroenterology. 2022;163(1):137-151. <doi:10.1053/j.gastro.2022.04.017>
8. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Drossman DA, Tack J, Ford AC, et al. Gastroenterology. 2018;154(4):1140-1171.e1. <doi:10.1053/j.gastro.2017.11.279>
9. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Ford AC, Moayyedi P, Chey WD, et al. The American Journal of Gastroenterology. 2018;113(Suppl 2):1-18. <doi:10.1038/s41395-018-0084-x>
10. AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review. Keefer L, Ko CW, Ford AC. Clinical Gastroenterology and Hepatology. 2021;19(12):2481-2488.e1. <doi:10.1016/j.cgh.2021.07.006>
11. Management of the Multiple Symptoms of Irritable Bowel Syndrome. Simren M, Tornblom H, Palsson OS, Whitehead WE. The Lancet. Gastroenterology & Hepatology. 2017;2(2):112-122. <doi:10.1016/S2468-1253(16)30116-9>
12. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Lacy BE, Pimentel M, Brenner DM, et al. The American Journal of Gastroenterology. 2021;116(1):17-44. <doi:10.14309/ajg.0000000000001036>
13. Efficacy of Psychological Therapies for Irritable Bowel Syndrome: Systematic Review and Network Meta-Analysis. Black CJ, Thakur ER, Houghton LA, et al. Gut. 2020;69(8):1441-1451. <doi:10.1136/gutjnl-2020-321191>
14. Review Article: Gut-Directed Hypnotherapy in the Management of Irritable Bowel Syndrome and Inflammatory Bowel Disease. Peters SL, Muir JG, Gibson PR. Alimentary Pharmacology & Therapeutics. 2015;41(11):1104-1115. <doi:10.1111/apt.13202>
15. Irritable Bowel Syndrome. Ford AC, Sperber AD, Corsetti M, Camilleri M. Lancet (London, England). 2020;396(10263):1675-1688. <doi:10.1016/S0140-6736(20)31548-8>
16. Gut-Focused Hypnotherapy for Functional Gastrointestinal Disorders: Evidence-Base, Practical Aspects, and the Manchester Protocol. Vasant DH, Whorwell PJ. Neurogastroenterology and Motility. 2019;31(8):e13573. <doi:10.1111/nmo.13573>
17. Comparison of Digitally Delivered Gut-Directed Hypnotherapy Program With an Active Control for Irritable Bowel Syndrome. Anderson EJ, Peters SL, Gibson PR, Halmos EP. The American Journal of Gastroenterology. 2025;120(2):440-448. <doi:10.14309/ajg.0000000000002921>
18. Gut-Directed Hypnosis and Hypnotherapy for Irritable Bowel Syndrome: A Mini-Review. Hauser W. Frontiers in Psychology. 2024;15:1389911. <doi:10.3389/fpsyg.2024.1389911>
19. AGA Institute Quality Indicator Development for Irritable Bowel Syndrome. Hung KW, Leiman DA, Kaza A, et al. Gastroenterology. 2025;168(3):612-622.e4. <doi:10.1053/j.gastro.2024.11.003>
20. Irritable Bowel Syndrome. Ford AC, Lacy BE, Talley NJ. The New England Journal of Medicine. 2017;376(26):2566-2578. <doi:10.1056/NEJMra1607547>